- Home
- QSG vs YMAB Comparison
QSG vs YMAB Comparison
Compare QSG & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSG
- YMAB
- Stock Information
- Founded
- QSG 2019
- YMAB 2015
- Country
- QSG China
- YMAB United States
- Employees
- QSG N/A
- YMAB N/A
- Industry
- QSG Other Consumer Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- QSG Real Estate
- YMAB Health Care
- Exchange
- QSG Nasdaq
- YMAB Nasdaq
- Market Cap
- QSG 441.6M
- YMAB 386.7M
- IPO Year
- QSG 2023
- YMAB 2018
- Fundamental
- Price
- QSG $11.45
- YMAB $8.60
- Analyst Decision
- QSG Buy
- YMAB Buy
- Analyst Count
- QSG 2
- YMAB 10
- Target Price
- QSG $5.81
- YMAB $13.91
- AVG Volume (30 Days)
- QSG 532.6K
- YMAB 921.6K
- Earning Date
- QSG 09-17-2025
- YMAB 11-07-2025
- Dividend Yield
- QSG 1.86%
- YMAB N/A
- EPS Growth
- QSG 92.28
- YMAB N/A
- EPS
- QSG 1.12
- YMAB N/A
- Revenue
- QSG $428,283,608.00
- YMAB $85,385,000.00
- Revenue This Year
- QSG N/A
- YMAB N/A
- Revenue Next Year
- QSG N/A
- YMAB $13.97
- P/E Ratio
- QSG $7.84
- YMAB N/A
- Revenue Growth
- QSG N/A
- YMAB N/A
- 52 Week Low
- QSG $1.58
- YMAB $3.55
- 52 Week High
- QSG $15.64
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- QSG 71.42
- YMAB 80.88
- Support Level
- QSG $8.36
- YMAB $8.50
- Resistance Level
- QSG $8.98
- YMAB $8.56
- Average True Range (ATR)
- QSG 0.68
- YMAB 0.02
- MACD
- QSG 0.33
- YMAB -0.13
- Stochastic Oscillator
- QSG 98.51
- YMAB 93.75
About QSG QuantaSing Group Limited
QuantaSing Group Ltd is a lifestyle solution provider. The company offers engaging, affordable, and accessible online and offline services, as well as consumer products in selected areas that address adult learners. The group has expanded into the pop toys sector and continues to strategically diversify its portfolio by capturing opportunities in consumer sectors while maintaining financial discipline.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.